RESUMO
Objective To compare and analysis of the clinical effect of Sanziyangqin decoction and ambroxol hydrochloride in the treatment of bronchiolitis.Methods 125 cases of bronchiolitis patients with complete data collected were retrospectively analyzed, randomly divided into control group ( 62 cases ) and observation group ( 63 cases ) , were treated with conventional ambroxol hydrochloride and Sanziyangqin decoction. The improvement of clinical symptoms, hospitalization time and treatment effect of the two groups were observed.Results The observation group of cough, wheezing, shortness of breath, throat phlegm and rales disappeared time and hospitalization time were significantly shorter than the control group, the difference was statistically significant (P<0.05).After treatment, the observation group of the total effective rate was 95.24%, significantly higher than the control group 72.58%, the difference was statistically significant (P<0.05).After Three months of treatment, the quality of life (GQOLI-74) was used to evaluate the scores of the patients in the two groups.The scores of the observation group were significantly higher than those of the control group, the difference was statistically significant (P<0.05).Before and after treatment in the two groups respectively were detected in blood and liver and kidney function, urine routine and other indicators, the detection and comparison were not abnormal, and the two groups before and after treatment were not found any adverse reaction.Conclusion The treatment of bronchiolitis in patients with Sanziyangqin decoction has the exact effect, compared with conventional ambroxol hydrochloride treatment can better improve the patient's clinical symptoms and signs, shorten the hospitalization time, improve the treatment efficiency and quality of life of patients, and there is no adverse reactions, is a safe and effective treatment method.
RESUMO
Objective To evaluate the clinical efficacy and safety of Kuanxionglif ei Decoction combined with Sanziyangqin Decoction,KXLFD-SZYQD) in treating acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with turbid phlegm obstructing lung syndrome, and to observe its effect on the lung function and routine blood tests. Methods Ninety patients meeting the diagnosis criteria were randomly divided into three groups. Thirty cases in KXLFD-SZYQD group were treated with western medicine and KXLFD-SZYQD, thirty cases in Kuanxionglif ei Decoction (KXLFD) group were treated with KXLFD and western medicine, and thirty cases administered with western medicine alone were taken as controls. The therapeutic course was 7 d. The clinical therapeutic effects, accumulated scores of symptoms, pulmonary function and routine blood test were observed before and after treatment. Results (1) The total effective rates of KXLFD-SZYQD group, KXLFD group and control group were 93.3% (28/30) , 80.0% (24/30) and 66.7% (20/30) , respectively , with significant difference found between KXLFD-SZYQD group and control group (P = 0.01). (2) The accumulated scores of symptoms showed that the improvement in KXLFD-SZYQD group was significantly greater than those in the other two groups (P = 0.018 , P = 0.000) , and the improvement of KXLFD group was significantly greater than that of the control group (P = 0.027). (3) Compared with control group , KXLFD-SZYQD group also had significantly improved FEV1 , FEV1/FVC%, WBC and NEUT% (P = 0.003, P =0.000, 7 = 0. 001, and P = 0.003, respectively) , and compared with KXLFD group, the improvement in KXLFD group was greater than that in the control group, but without significant difference (P=0.032, 0. 037, 0. 037,and 0. 034, respectively). (4) The vital signs of the three groups were stable during the treatment, and there were no damage to the heart , liver or kidney and no other serious complications. Conclusion KXLFD-SZYQD combined with western medicine treatment can decrease WBC count and neutrophil percent , improve lung function and the clinical condition of AECOPD patients with turbid phlegm obstructing lung syndrome.